Cargando…

Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer

OBJECTIVE: To investigate chemokine receptor CXCR1 expression characteristic in different breast tissues and analyze the relationship between CXCR1 expression changes in breast cancer tissue and efficacy of neo-adjuvant chemotherapy. RESULTS: Chemokine receptor CXCR1 was lowly expressed in normal br...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Miao-Qun, Liu, Jun, Sang, Jian-Feng, Su, Lei, Yao, Yong-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564737/
https://www.ncbi.nlm.nih.gov/pubmed/28454081
http://dx.doi.org/10.18632/oncotarget.16893
_version_ 1783258291615301632
author Xue, Miao-Qun
Liu, Jun
Sang, Jian-Feng
Su, Lei
Yao, Yong-Zhong
author_facet Xue, Miao-Qun
Liu, Jun
Sang, Jian-Feng
Su, Lei
Yao, Yong-Zhong
author_sort Xue, Miao-Qun
collection PubMed
description OBJECTIVE: To investigate chemokine receptor CXCR1 expression characteristic in different breast tissues and analyze the relationship between CXCR1 expression changes in breast cancer tissue and efficacy of neo-adjuvant chemotherapy. RESULTS: Chemokine receptor CXCR1 was lowly expressed in normal breast tissues and breast fibroadenoma, but highly expressed in breast cancer. It was significantly correlated with pathological stage, tumor cell differentiation, and lymph node metastasis (P < 0.05). After neo-adjuvant chemotherapy, CXCR1 expression in breast cancer tissues decreased. Among these 104 breast cancer patients with different molecular subtypes, the survival rate with Luminal A was the highest, followed by the Luminal B breast cancer, TNBC was the worst. MATERIALS AND METHODS: 104 cases with breast carcinoma, 20 cases with normal breast and 20 cases with breast fibroadenoma were included and followed up. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues. The relationship between the CXCR1 expression changes in breast cancer biopsies and surgical specimens, as well as the efficacy of neo-adjuvant chemotherapy, was analyzed. CONCLUSIONS: Chemokine receptor CXCR1 could be used as an indicator to predict benign or malignant breast disease, and it can even predict the malignancy degree of breast cancer, as well as its invasive ability and prognosis.
format Online
Article
Text
id pubmed-5564737
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55647372017-08-23 Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer Xue, Miao-Qun Liu, Jun Sang, Jian-Feng Su, Lei Yao, Yong-Zhong Oncotarget Research Paper OBJECTIVE: To investigate chemokine receptor CXCR1 expression characteristic in different breast tissues and analyze the relationship between CXCR1 expression changes in breast cancer tissue and efficacy of neo-adjuvant chemotherapy. RESULTS: Chemokine receptor CXCR1 was lowly expressed in normal breast tissues and breast fibroadenoma, but highly expressed in breast cancer. It was significantly correlated with pathological stage, tumor cell differentiation, and lymph node metastasis (P < 0.05). After neo-adjuvant chemotherapy, CXCR1 expression in breast cancer tissues decreased. Among these 104 breast cancer patients with different molecular subtypes, the survival rate with Luminal A was the highest, followed by the Luminal B breast cancer, TNBC was the worst. MATERIALS AND METHODS: 104 cases with breast carcinoma, 20 cases with normal breast and 20 cases with breast fibroadenoma were included and followed up. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues. The relationship between the CXCR1 expression changes in breast cancer biopsies and surgical specimens, as well as the efficacy of neo-adjuvant chemotherapy, was analyzed. CONCLUSIONS: Chemokine receptor CXCR1 could be used as an indicator to predict benign or malignant breast disease, and it can even predict the malignancy degree of breast cancer, as well as its invasive ability and prognosis. Impact Journals LLC 2017-04-06 /pmc/articles/PMC5564737/ /pubmed/28454081 http://dx.doi.org/10.18632/oncotarget.16893 Text en Copyright: © 2017 Xue et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Xue, Miao-Qun
Liu, Jun
Sang, Jian-Feng
Su, Lei
Yao, Yong-Zhong
Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
title Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
title_full Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
title_fullStr Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
title_full_unstemmed Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
title_short Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
title_sort expression characteristic of cxcr1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564737/
https://www.ncbi.nlm.nih.gov/pubmed/28454081
http://dx.doi.org/10.18632/oncotarget.16893
work_keys_str_mv AT xuemiaoqun expressioncharacteristicofcxcr1indifferentbreasttissuesandtherelevancebetweenitsexpressionandefficacyofneoadjuvantchemotherapyinbreastcancer
AT liujun expressioncharacteristicofcxcr1indifferentbreasttissuesandtherelevancebetweenitsexpressionandefficacyofneoadjuvantchemotherapyinbreastcancer
AT sangjianfeng expressioncharacteristicofcxcr1indifferentbreasttissuesandtherelevancebetweenitsexpressionandefficacyofneoadjuvantchemotherapyinbreastcancer
AT sulei expressioncharacteristicofcxcr1indifferentbreasttissuesandtherelevancebetweenitsexpressionandefficacyofneoadjuvantchemotherapyinbreastcancer
AT yaoyongzhong expressioncharacteristicofcxcr1indifferentbreasttissuesandtherelevancebetweenitsexpressionandefficacyofneoadjuvantchemotherapyinbreastcancer